Endeavor BioMedicines, a clinical-stage biotech company, has announced promising phase 2a trial results for its lead investigational candidate, ENV-101.
Vicore Pharma has entered into an exclusive licensing agreement with Japanese pharmaceutical company Nippon Shinyaku to commercialize Vicore’s idiopathic pulmonary fibrosis (IPF) drug candidate C21 in Japan.